Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia

Eltrombopag, an FDA-approved non-peptidyl thrombopoietin receptor agonist, is clinically used for the treatment of aplastic anemia, a disease characterized by hematopoietic stem cell failure and pancytopenia, to improve platelet counts and stem cell function. Eltrombopag treatment results in a durab...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Yihong, Hasipek, Metis, Jiang, Dongxu, Tiwari, Anand D., Grabowski, Dale R., Pagliuca, Simona, Kongkiatkamon, Sunisa, Patel, Bhumika, Singh, Salendra, Parker, Yvonne, LaFramboise, Thomas, Lindner, Daniel, Sekeres, Mikkael A., Mian, Omar Y., Saunthararajah, Yogen, Maciejewski, Jaroslaw P., Jha, Babal K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843742/
https://www.ncbi.nlm.nih.gov/pubmed/35085104
http://dx.doi.org/10.1172/JCI149856

Ejemplares similares

Ejemplares similares